Biotech Values

[bellweather1]

TGTX:TG-1101/Ibrutinib EHA Combo Data

Hi GD,

Just noticed that a preliminary peek at first combo data this Wed.(May 21,2014)via abstract, will likely only be for the above combo,(TGTXs anti CD-20 & Ibrutinib), and will probably not include combo data on TGTXs TGR-1202/TG-1101 combo.

According to guidance from the last presentation slides(May 7,2014, see below), we'll have to wait till the Pan Pacific Lymphoma conference(in July) for the latter. Not sure if they release early abstracts for this one.

However, looking forward to this Ibrutinib combo data-I believe it will be first such anti CD-20 combo since the Ofatumumab/Ibrutinib data at ASCO.

2014 Milestones (see pg23 of PDF linked below)

1H 2014 Determine optimal dosing for TGR-1202 as single agent

Enroll Ph. 2 TG-1101 + Ibrutinib in CLL and MCL

Enroll Ph. 2 TG-1101 + TGR-1202 in B-cell Malignancies

Q2 2014 ASCO - Present updated single agent data for TG-1101 & TGR1202

EHA - Present prelim combo data for TG-1101 + Ibrutinib (June, 2014)

Q3 2014 Pan-Pacific - Present prelim combo data for TG-1101 + TGR-1202 (July, 2014)

2H 2014 Commence combination registration trial(s)

Q4 2014 Present updated combo data and single agent TGR-1202 data

http://files.shareholder.com/downloads/MHA/3008734518x0x753325/1106d1c2-a7ec-49cd-bb0a-dc8471e1f2b3/TG_Therapeutics_Corporate_Presentaton_May_2014_DB_Conference.pdf


Regards,

bw